Q2 Earnings Estimate for Liquidia Issued By HC Wainwright

Liquidia Co. (NASDAQ:LQDA) – Equities research analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for Liquidia in a report released on Thursday, March 20th. HC Wainwright analyst A. Fein anticipates that the company will post earnings per share of ($0.46) for the quarter. HC Wainwright currently has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.25) EPS and FY2029 earnings at $0.51 EPS.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. The company had revenue of $2.92 million during the quarter, compared to the consensus estimate of $4.60 million.

LQDA has been the topic of a number of other research reports. Wells Fargo & Company initiated coverage on Liquidia in a research report on Friday, December 20th. They issued an “overweight” rating and a $20.00 target price on the stock. Needham & Company LLC lifted their target price on Liquidia from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Scotiabank lifted their target price on Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $26.63.

Liquidia Stock Down 2.1 %

Liquidia stock opened at $15.12 on Friday. Liquidia has a 12-month low of $8.26 and a 12-month high of $16.92. The business’s 50-day moving average price is $14.79 and its two-hundred day moving average price is $12.20. The stock has a market cap of $1.28 billion, a PE ratio of -9.28 and a beta of 0.07.

Insider Buying and Selling

In other Liquidia news, CFO Michael Kaseta sold 23,370 shares of the firm’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total transaction of $275,298.60. Following the completion of the transaction, the chief financial officer now owns 401,755 shares in the company, valued at approximately $4,732,673.90. This trade represents a 5.50 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Rajeev Saggar sold 6,249 shares of the business’s stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $11.78, for a total transaction of $73,613.22. Following the completion of the transaction, the insider now owns 270,388 shares in the company, valued at $3,185,170.64. This trade represents a 2.26 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,245 shares of company stock valued at $843,326 in the last three months. Insiders own 30.10% of the company’s stock.

Institutional Investors Weigh In On Liquidia

Several large investors have recently modified their holdings of the company. California State Teachers Retirement System increased its position in shares of Liquidia by 17.5% during the fourth quarter. California State Teachers Retirement System now owns 51,928 shares of the company’s stock worth $611,000 after buying an additional 7,725 shares during the period. Toronto Dominion Bank acquired a new stake in shares of Liquidia during the fourth quarter worth $235,000. Alpine Global Management LLC increased its position in shares of Liquidia by 50.0% during the fourth quarter. Alpine Global Management LLC now owns 150,000 shares of the company’s stock worth $1,764,000 after buying an additional 50,000 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Liquidia by 26.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 105,734 shares of the company’s stock worth $1,243,000 after buying an additional 22,445 shares during the period. Finally, Whitefort Capital Management LP increased its position in shares of Liquidia by 16.8% during the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company’s stock worth $23,370,000 after buying an additional 285,220 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).